Jazz Pharmaceuticals
Presence
Jazz Pharmaceuticals is one of the...
Jazz Pharmaceuticals is a company listed under the stock ticker JAZZ (IE).
Jazz Pharmaceuticals has a direct presence in 3 countries.
Executives
View the org chart displaying its 35 main executives
Most searched biographies at Jazz Pharmaceuticals
- Bruce Cozadd, Chairman and Chief Executive Officer
- Seamus Mulligan, Director
- Kenneth O'Keefe, Director
Popular executive movements at Jazz Pharmaceuticals
- Patrick Kennedy has joined the company as Director (posted on February 28 2024).
- Philip Johnson will join the company as Executive Vice President and Chief Financial Officer on Mar. 15, 2024 (posted on February 22 2024).
- Daniel Swisher, President and Chief Operating Officer, will retire on Oct. 1, 2023 (posted on September 13 2023).
Click here to view some more movements at Jazz Pharmaceuticals
Create your alert
to follow the executive moves at Jazz Pharmaceuticals.
Pharmaceuticals
Jazz Pharmaceuticals has 1,865 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Jazz Pharmaceuticals
- Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022 | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals and Redx Announce Pan-RAF Inhibitor JZP815 to Enter Clinical Development | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist | Jazz Pharmaceuticals plc
- View more press releases Close
Social media about Jazz Pharmaceuticals
- Jazz Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Jazz Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Bruce Cozadd 
Call Jazz Pharmaceuticals at +1 650...
